ATE517920T1 - Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) - Google Patents

Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)

Info

Publication number: ATE517920T1
Authority: AT; Austria
Prior art keywords: ifnar; humanized antibodies; antibodies against; interferon alpha; alpha receptor
Prior art date: 2003-04-23

Application number

AT04750579T

Other languages

English (en)

Inventor

Josephine Cardarelli

Tseng-Hui Chen

David King

Christopher Bebbington

Sarah Pogue

Francis J Carr

Stephen Williams

Original Assignee

Medarex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-23

Filing date

2004-04-23

Publication date

2011-08-15

2004-04-23 Application filed by Medarex Inc filed Critical Medarex Inc

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE517920T1 publication Critical patent/ATE517920T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Neurology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04750579T 2003-04-23 2004-04-23 Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) ATE517920T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46505803P	2003-04-23	2003-04-23
PCT/US2004/012649 WO2004094473A2 (en)	2003-04-23	2004-04-23	Humanized antibodies to interferon alpha receptor-1 (ifnar-1)

Publications (1)

Publication Number	Publication Date
ATE517920T1 true ATE517920T1 (de)	2011-08-15

Family

ID=33310989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04750579T ATE517920T1 (de)	2003-04-23	2004-04-23	Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)

Country Status (14)

Country	Link
US (3)	US7619070B2 (de)
EP (2)	EP1631590B1 (de)
JP (3)	JP2007525458A (de)
KR (2)	KR20080045765A (de)
CN (1)	CN1795010A (de)
AT (1)	ATE517920T1 (de)
AU (1)	AU2004233346B2 (de)
BR (1)	BRPI0410492A (de)
CA (1)	CA2523142A1 (de)
ES (1)	ES2368737T3 (de)
MX (1)	MXPA05011406A (de)
NZ (1)	NZ542988A (de)
WO (1)	WO2004094473A2 (de)
ZA (1)	ZA200508389B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100951409B1 (ko)	2001-01-09	2010-04-07	베일러 리서치 인스티튜트	수지상 세포로의 단핵세포 분화를 억제하는 조성물 및 이를 포함하는 키트
SG173919A1 (en)	2003-04-23	2011-09-29	Medarex Inc	Compositions and methods for the therapy of inflammatory bowel disease
CA2523142A1 (en) *	2003-04-23	2004-11-04	Medarex, Inc.	Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
AU2011236019B2 (en) *	2004-06-21	2012-12-13	E. R. Squibb & Sons, L.L.C.	Interferon alpha receptor 1 antibodies and their uses
KR20130012258A (ko) *	2004-06-21	2013-02-01	메다렉스, 인코포레이티드	인터페론 알파 수용체 1 항체 및 그의 용도
US20060019342A1 (en) *	2004-06-25	2006-01-26	Medimmune, Inc.	Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
US7888481B2 (en)	2005-02-10	2011-02-15	Baylor Research Institute	Anti-interferon alpha monoclonal antibodies and methods for use
KR101363120B1 (ko)	2005-02-10	2014-02-13	베일러 리서치 인스티튜트	항-인터페론 알파 모노클로날 항체 및 사용 방법
EA015629B1 (ru) *	2005-08-11	2011-10-31	Арпи Матоссиан-Роджерс	Пептиды, используемые для лечения и диагностики аутоиммунных заболеваний
ES2471444T3 (es)	2006-04-24	2014-06-26	Genentech, Inc.	Métodos y composiciones para detectar trastornos autoinmunitarios
JP2007306828A (ja) *	2006-05-17	2007-11-29	Tokai Univ	非還元マンノース残基を認識するファージ提示型単鎖抗体
US20090010966A1 (en) *	2007-06-21	2009-01-08	Angelica Therapeutics, Inc.	Modified diphtheria toxins
US8470314B2 (en) *	2008-02-29	2013-06-25	Angelica Therapeutics, Inc.	Modified toxins
JP2012506695A (ja) *	2008-08-20	2012-03-22	ヤンセンバイオテツク，インコーポレーテツド	改変された抗ｉｌ−１３抗体、組成物、方法、及び使用
GB0817891D0 (en)	2008-09-30	2008-11-05	Medical Res Council	Antibodies against il-25
WO2011028933A1 (en)	2009-09-03	2011-03-10	Medimmune, Llc	Type 1 interferon diagnostic
JP5310878B2 (ja)	2011-02-17	2013-10-09	株式会社ニコン	投射型表示装置、携帯型電子機器およびデジタルカメラ
US9402994B2 (en)	2011-07-14	2016-08-02	Cyberonics, Inc.	Powering of an implantable medical therapy delivery device using far field radiative powering at multiple frequencies
WO2014150600A2 (en)	2013-03-15	2014-09-25	Angelica Therapeutics, Inc.	Modified toxins
TWI713453B (zh) *	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
US11136399B2 (en)	2016-07-14	2021-10-05	Institute Of Biophysics, Chinese Academy Of Sciences	Type I interferon receptor antibody and use thereof
SG11202101946YA (en) *	2018-09-18	2021-04-29	I Mab Biopharma Hangzhou Co Ltd	Anti-ifnar1 antibodies for treating autoimmune diseases
US20220144957A1 (en) *	2019-01-31	2022-05-12	Immunecent Biotechnology, Inc.	Novel anti-ifnar1 antibodies
WO2020165437A1 (en)	2019-02-15	2020-08-20	Astrazeneca Ab	Type i interferon-mediated disorders
CN113521276B (zh) *	2021-07-13	2022-04-12	江苏荃信生物医药股份有限公司	包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US5156840A (en)	1982-03-09	1992-10-20	Cytogen Corporation	Amine-containing porphyrin derivatives
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US5374548A (en)	1986-05-02	1994-12-20	Genentech, Inc.	Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es)	1985-06-26	1992-08-01	Liposome Co Inc	Metodo para acoplamiento de liposomas.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5057313A (en)	1986-02-25	1991-10-15	The Center For Molecular Medicine And Immunology	Diagnostic and therapeutic antibody conjugates
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
IL78444A (en) *	1986-04-08	1992-05-25	Yeda Res & Dev	Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
US5889151A (en)	1989-10-20	1999-03-30	Societe Leb-Tech	Purified human alpha interferon receptor
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
EP0563487A1 (de) *	1992-03-31	1993-10-06	Laboratoire Europeen De Biotechnologie S.A.	Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
GB9223377D0 (en)	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
EP0725654A1 (de) *	1993-09-17	1996-08-14	Laboratoire Europeen De Biotechnologie S.A.	Pharmazeutische zusammensetzung mit monoklonale antikoerpern gegen den interferenrezeptor, mit neutralisierender wirkung gegen typ i interferon
US5818453A (en) *	1996-01-05	1998-10-06	Weavexx Corporation	System for evaluating print quality for a sheet
DE69737188T2 (de) *	1996-05-04	2007-10-11	Astrazeneca Ab	Monoklonaler antikoerper gegen cea, konjugate die dieses antikoerper enthalten und deren therapeutische verwendung in einem adept-system
WO1998023761A1 (en) *	1996-11-27	1998-06-04	Genentech, Inc.	HUMANIZED ANTI-CD11a ANTIBODIES
EP0983303B1 (de) *	1997-05-21	2006-03-08	Biovation Limited	Verfahren zur herstellung von nicht-immunogenen proteinen
WO2000058362A1 (en) *	1999-03-26	2000-10-05	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
WO2001000245A2 (en) *	1999-06-25	2001-01-04	Genentech, Inc.	HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
GB0001712D0 (en) *	2000-01-25	2000-03-15	Pharma Pacific Pty Ltd	Therapeutic peptides
GB0001710D0 (en) *	2000-01-25	2000-03-15	Pharma Pacific Pty Ltd	Therapeutic treatment
HU227039B1 (en)	2000-01-25	2010-05-28	Egis Gyogyszergyar Nyilvanosan	New process for the production of quetiapine and intermediates therefor
WO2003025019A1 (en) *	2001-09-20	2003-03-27	Alexion Pharmaceuticals, Inc.	Anti-pdgf antibodies and methods for producing engineered antibodies
SG173919A1 (en) *	2003-04-23	2011-09-29	Medarex Inc	Compositions and methods for the therapy of inflammatory bowel disease
CA2523142A1 (en) *	2003-04-23	2004-11-04	Medarex, Inc.	Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
US8162912B2 (en)	2008-05-30	2012-04-24	Kimberly Clark Worldwide, Inc.	Personal wear absorbent article with disposal tab

2004
- 2004-04-23 CA CA002523142A patent/CA2523142A1/en not_active Abandoned
- 2004-04-23 ES ES04750579T patent/ES2368737T3/es not_active Expired - Lifetime
- 2004-04-23 WO PCT/US2004/012649 patent/WO2004094473A2/en active Application Filing
- 2004-04-23 NZ NZ542988A patent/NZ542988A/en unknown
- 2004-04-23 US US10/831,459 patent/US7619070B2/en not_active Expired - Fee Related
- 2004-04-23 CN CNA2004800141023A patent/CN1795010A/zh active Pending
- 2004-04-23 KR KR1020087010204A patent/KR20080045765A/ko not_active Ceased
- 2004-04-23 KR KR1020057020179A patent/KR100872210B1/ko not_active Expired - Fee Related
- 2004-04-23 EP EP04750579A patent/EP1631590B1/de not_active Expired - Lifetime
- 2004-04-23 EP EP10011473A patent/EP2404615A1/de not_active Withdrawn
- 2004-04-23 AT AT04750579T patent/ATE517920T1/de not_active IP Right Cessation
- 2004-04-23 JP JP2006513277A patent/JP2007525458A/ja active Pending
- 2004-04-23 MX MXPA05011406A patent/MXPA05011406A/es unknown
- 2004-04-23 BR BRPI0410492-7A patent/BRPI0410492A/pt not_active IP Right Cessation
- 2004-04-23 AU AU2004233346A patent/AU2004233346B2/en not_active Ceased
2005
- 2005-10-17 ZA ZA200508389A patent/ZA200508389B/xx unknown
2009
- 2009-09-28 JP JP2009223533A patent/JP2009298818A/ja active Pending
- 2009-09-29 US US12/569,205 patent/US7888484B2/en not_active Expired - Fee Related
2010
- 2010-11-18 JP JP2010258382A patent/JP2011032292A/ja active Pending
- 2010-12-20 US US12/972,813 patent/US8758757B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2004094473A2 (en)	2004-11-04
US20100104569A1 (en)	2010-04-29
AU2004233346A1 (en)	2004-11-04
EP1631590A2 (de)	2006-03-08
JP2009298818A (ja)	2009-12-24
CA2523142A1 (en)	2004-11-04
BRPI0410492A (pt)	2006-06-13
ZA200508389B (en)	2006-10-25
EP2404615A1 (de)	2012-01-11
MXPA05011406A (es)	2005-12-12
US7888484B2 (en)	2011-02-15
EP1631590B1 (de)	2011-07-27
KR20060011968A (ko)	2006-02-06
US7619070B2 (en)	2009-11-17
US8758757B2 (en)	2014-06-24
US20110086422A1 (en)	2011-04-14
ES2368737T3 (es)	2011-11-21
US20050208041A1 (en)	2005-09-22
AU2004233346B2 (en)	2008-03-06
CN1795010A (zh)	2006-06-28
KR20080045765A (ko)	2008-05-23
WO2004094473A3 (en)	2005-06-02
KR100872210B1 (ko)	2008-12-05
JP2007525458A (ja)	2007-09-06
JP2011032292A (ja)	2011-02-17
NZ542988A (en)	2008-07-31

Publication	Publication Date	Title
ATE517920T1 (de)	2011-08-15	Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
WO2005103081A3 (en)	2005-12-01	Human monoclonal antibodies against cd20
CY1119454T1 (el)	2018-03-07	Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1112277T1 (el)	2015-12-09	ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE502052T1 (de)	2011-04-15	Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
DK1406656T3 (da)	2013-04-15	Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
EA201100923A1 (ru)	2011-12-30	Антитела человека против тканевого фактора
CY1111622T1 (el)	2015-10-07	Ανθρωποποιημενοι ανταγωνιστες anti-cmet
ATE455127T1 (de)	2010-01-15	Humane anti-humane cd3-bindungsmoleküle
WO2007062245A3 (en)	2007-12-06	Human monoclonal antibody human cd134 (ox40) and methods of making and using same
DK1734995T3 (da)	2010-10-25	Monoklonale antistoffer og hepatocyytvækstfaktor
RS80704A (en)	2006-12-15	ANTI- av?6.ANTIBODIES
CY1113224T1 (el)	2016-04-13	Νεο αντισωμα αντι-ρlgf
MX2010005022A (es)	2010-06-02	Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
TW200722437A (en)	2007-06-16	Anti-TrkB monoclonal antibodies and uses thereof
TNSN06087A1 (en)	2007-10-03	Therapeutic binding molecules
BR0315157A (pt)	2005-08-09	Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
DK1572946T3 (da)	2012-07-02	Terapeutisk humant monoklonalt anti-IL-1R1-antistof
ATE517340T1 (de)	2011-08-15	Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
DK1411962T3 (da)	2011-04-04	Terapi for pancreacancer med monoklonalt stof
EA200702634A1 (ru)	2008-06-30	Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
UA98100C2 (ru)	2012-04-25	Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
EA202190387A1 (ru)	2022-01-31	Антитело к cd38 человека и его применение
CY1116887T1 (el)	2017-04-05	Anti-cd19 αντισωματα και χρησεις στην ογκολογια
TH71073A (th)	2005-10-13	แอนติบอดีโมเลกุลที่มีความจำเพาะสำหรับ il-1(เบตา) ของคน

Legal Events

Date	Code	Title	Description
2012-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties